Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Perlecan Domain V Inhibits Amyloid-β Induced Activation of the α2β1 Integrin-Mediated Neurotoxic Signaling Cascade.

Parham CL, Shaw C, Auckland LD, Dickeson SK, Griswold-Prenner I, Bix G.

J Alzheimers Dis. 2016 Oct 18;54(4):1629-1647.

PMID:
27636841
2.

Lipoprotein binding to anionic biopolyelectrolytes and the effect of glucose on nanoplaque formation in arteriosclerosis and Alzheimer's disease.

Siegel G, Mockenhaupt FHME, Behnke AL, Ermilov E, Winkler K, Pries AR, Malmsten M, Hetzer R, Saunders R, Lindman B.

Adv Colloid Interface Sci. 2016 Jun;232:25-35. doi: 10.1016/j.cis.2016.02.001. Epub 2016 Feb 19. Review.

PMID:
26969281
3.

Early changes in extracellular matrix in Alzheimer's disease.

Lepelletier FX, Mann DM, Robinson AC, Pinteaux E, Boutin H.

Neuropathol Appl Neurobiol. 2017 Feb;43(2):167-182. doi: 10.1111/nan.12295. Epub 2015 Nov 30.

PMID:
26544797
4.

The potential role of perlecan domain V as novel therapy in vascular dementia.

Marcelo A, Bix G.

Metab Brain Dis. 2015 Feb;30(1):1-5. doi: 10.1007/s11011-014-9576-6. Epub 2014 Jun 27. Review.

PMID:
24964971
5.

Perlecan domain V inhibits amyloid-β induced brain endothelial cell toxicity and restores angiogenic function.

Parham C, Auckland L, Rachwal J, Clarke D, Bix G.

J Alzheimers Dis. 2014;38(2):415-23. doi: 10.3233/JAD-130683.

6.

Characterization of amyloid-β granules in the hippocampus of SAMP8 mice.

Manich G, Mercader C, del Valle J, Duran-Vilaregut J, Camins A, Pallàs M, Vilaplana J, Pelegrí C.

J Alzheimers Dis. 2011;25(3):535-46. doi: 10.3233/JAD-2011-101713.

PMID:
21460438
7.

Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease.

Lam V, Takechi R, Pallebage-Gamarallage MM, Galloway S, Mamo JC.

Neurosci Lett. 2011 Apr 4;492(3):160-4. doi: 10.1016/j.neulet.2011.02.001. Epub 2011 Feb 15.

PMID:
21310214
8.

Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy.

Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO.

Acta Neuropathol. 2011 Apr;121(4):431-43. doi: 10.1007/s00401-011-0801-7. Epub 2011 Jan 23.

PMID:
21259015
9.

Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.

Wright S, Parham C, Lee B, Clarke D, Auckland L, Johnston J, Lawrence AL, Dickeson SK, Santoro SA, Griswold-Prenner I, Bix G.

Neurobiol Aging. 2012 Jul;33(7):1379-88. doi: 10.1016/j.neurobiolaging.2010.10.018. Epub 2010 Dec 3.

PMID:
21126803
10.

Limited expression of heparan sulphate proteoglycans associated with Aβ deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease.

Timmer NM, Herbert MK, Kleinovink JW, Kiliaan AJ, De Waal RM, Verbeek MM.

Neuropathol Appl Neurobiol. 2010 Oct;36(6):478-86. doi: 10.1111/j.1365-2990.2010.01091.x.

PMID:
20831743
11.

HSPG2 gene C/A polymorphism does not confer susceptibility to Alzheimer's disease in Chinese.

Wang B, Jin F, Yang Z, Lu Z, Zheng C, Wang L.

Dement Geriatr Cogn Disord. 2007;23(5):312-5. Epub 2007 Mar 15.

PMID:
17356275
12.

Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study.

Lashley T, Holton JL, Verbeek MM, Rostagno A, Bojsen-Møller M, David G, van Horssen J, Braendgaard H, Plant G, Frangione B, Ghiso J, Revesz T.

Neuropathol Appl Neurobiol. 2006 Oct;32(5):492-504.

PMID:
16972883
13.

The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane.

Mok SS, Losic D, Barrow CJ, Turner BJ, Masters CL, Martin LL, Small DH.

J Neurochem. 2006 Jan;96(1):53-64. Epub 2005 Nov 3.

14.

An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease.

Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, Grenader T, Wertman E, Abramsky O.

Am J Med Genet B Neuropsychiatr Genet. 2004 Jul 1;128B(1):123-5.

PMID:
15211644
15.

Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques.

van Horssen J, Kleinnijenhuis J, Maass CN, Rensink AA, Otte-Höller I, David G, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM.

Neurobiol Aging. 2002 Jul-Aug;23(4):537-45.

PMID:
12009503
16.

Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains.

van Horssen J, Otte-Höller I, David G, Maat-Schieman ML, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM.

Acta Neuropathol. 2001 Dec;102(6):604-14.

PMID:
11761721
17.

Overproduction of perlecan core protein in cultured cells and transgenic mice.

Hart M, Li L, Tokunaga T, Lindsey JR, Hassell JR, Snow AD, Fukuchi K.

J Pathol. 2001 Jun;194(2):262-9.

PMID:
11400157
18.

Laminin inhibition of beta-amyloid protein (Abeta) fibrillogenesis and identification of an Abeta binding site localized to the globular domain repeats on the laminin a chain.

Castillo GM, Lukito W, Peskind E, Raskind M, Kirschner DA, Yee AG, Snow AD.

J Neurosci Res. 2000 Nov 1;62(3):451-62.

PMID:
11054814
19.

A beta and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity.

Holcomb LA, Gordon MN, Benkovic SA, Morgan DG.

Mech Ageing Dev. 2000 Jan 3;112(2):135-52.

PMID:
10690926
20.

Supplemental Content

Loading ...
Support Center